Shots:

• The P-III POSEIDON study involves assessing of Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment in patients with non-squamous or squamous mNSCLC with all PD-L1 expression levels
• The P-III POSEIDON study resulted in meeting its 1EPs & 2EPs i.e- improvement in final PFS analysis in patients treated with Imfinzi + SoC platinum-based CT & improvement in PFS in patients treated with triple regimen respectively
• Imfinzi is a mAb targeting PD-L1- blocking the interaction of PD-L1 with PD-1 and CD80 with its anticipated additional 1EPs of OS data in 2020 while Tremelimumab is a mAb targeting the activity CTLA-4- contributing to T cell activation and boosting the immune response to cancer

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: Hindustan Times